Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3,5-Monophosphate and Decreases Mean Arterial Pressure

@article{Cataliotti2005OralHB,
  title={Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3,5-Monophosphate and Decreases Mean Arterial Pressure},
  author={Alessandro Cataliotti and John A. Schirger and Fernando L. Martin and Horng H. Chen and Paul M. McKie and Guido Boerrigter and Lisa C. Costello-Boerrigter and Gail J. Harty and Denise M. Heublein and Sharon M. Sandberg and Kenneth D. James and Mark A Miller and Navdeep B. Malkar and Karen Polowy and John C. Burnett},
  journal={Circulation},
  year={2005},
  volume={112},
  pages={836-840}
}
Background—The objective of this study was to address the feasibility and the biological activity of orally administered human brain natriuretic peptide (hBNP). Proprietary technology has been developed in which short, amphiphilic oligomers are covalently attached to peptides. The conjugated peptides are intended to have an improved pharmacokinetic profile and to enable oral administration. We hypothesized that novel oral conjugated hBNP (CONJ-hBNP) increases plasma hBNP, activates cGMP, and… 

Figures from this paper

Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
TLDR
A role for PDE V as contributing to renal maladaptation in a model of experimental overt CHF is supported and the strategy of maximizing the renal cGMP system by combined PDE VI and natriuretic peptides in CHF to improve renal function is supported.
Natriuretic peptides and myocardial structure: insights from population genetics.
TLDR
This study focuses attention on the processing of the cardiac peptide prohormones to mature biologically active peptides by the protease corin, established as the natriuretic peptide-converting enzyme for ANP and presumably BNP.
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
TLDR
The current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension is summarized.
Atrial Natriuretic Peptide - Old But New Therapeutic in Cardiovascular Diseases.
  • T. Ichiki, J. Burnett
  • Biology
    Circulation journal : official journal of the Japanese Circulation Society
  • 2017
TLDR
Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection, and engineering to develop ANP-based peptides for chronic use.
Natriuretic peptides and therapeutic applications
TLDR
The NP system thus serves as an important compensatory mechanism against neurohumoral activation in heart failure and provides a strong rationale for the use of exogenous NPs in the management of acutely decompensated heart failure.
Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis
TLDR
The dual effect of neprilysin inhibition and angiotensin receptor blockade has substantial implications on the natriuretic peptide axis (NPA) and there is evidence that the changes in BNP and NT-proBNP correlate with improvement in echocardiographic parameters of volume and function.
M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy
TLDR
M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP.
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
TLDR
The basic science and clinical research that has led to understanding of the role of BNP in cardiovascular physiology, its use as a biomarker of right ventricular function and its therapeutic potential for managing patients with pulmonary vascular disease are examined.
Pulmonary Hemodynamic Response to Acute Combination and Monotherapy With Sildenafil and Brain Natriuretic Peptide in Rats With Monocrotaline-Induced Pulmonary Hypertension
TLDR
This study suggests that intravenous administration of both sildenafil and BNP monotherapy produces significant improvement in RVSP, making them potentially viable options for the treatment of PAH, whereas combination therapy produces no additional improvement in pulmonary hemodynamics.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Brain natriuretic peptide is a novel cardiac hormone.
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
TLDR
Cardiorenal and humoral actions of 90 min of intravenous equimolar infusion of ANP, BNP, and Uro support the conclusion that in experimental overt CHF, renal resistance to natriuretic peptides in increasing rank order is BNP.
Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.
TLDR
Results indicate that BNP is a novel cardiac hormone secreted predominantly from the ventricle, and that the synthesis, secretion and clearance of BNP differ from those of ANP, suggesting discrete physiological and pathophysiological roles of HBNP in a dual natriuretic peptide system.
BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
TLDR
AHF is characterized by a failure to increase circulating BNP underscoring differential physiological and pathophysiological roles for ANP and BNP in states of immediate cardiac overload, and these studies also support a potential role for B NP in the therapeutics of AHF.
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
TLDR
This study supports the conclusion that chronic oral NEPI delays the onset of reduction in sodium excretion during the transition from early to severe CHF in this model of PCHF, indicating a therapeutic potential.
Albubnp, a Recombinant B-type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure
TLDR
AlbuBNP is bioactive and has desired pharmacokinetic properties for long-term use and has the potential to be further developed as a new therapeutic option for chronic, acute, and post-acute CHF to alleviate symptoms, improve clinical status, and slow the disease progression by sustained drug exposure via infrequent simple subcutaneous injections.
Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure
TLDR
Coadministration of BNP and loop diuretic is effective in maximizing natriuresis and diuresis while preserving renal function and inhibiting activation of aldosterone.
Natriuretic peptide system in human heart failure.
TLDR
These studies support a differential regulation of ANP, BNP, and CNP circulating concentrations and tissue activity in human CHF.
...
1
2
3
...